← Leaderboards
Ziyad Al-Aly
St. Louis Va Medical Center
$0
Attributed
$0
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2020–25$1$1$1$0$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 3
By mechanism
I01$0 · 2
I21$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Characteristics”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Hobbs · Suny At Stony Brook$41,239,084
- Phd, Stephen Schwartz · Fred Hutchinson Cancer Research Center$26,641,749
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$25,068,887
Research focus
CharacteristicsMethodologyCardiovascular DiseasesInnovationHazardCohortKidney DiseasesProbabilityHospitalizationFutureHigh DimensionalityIncidenceCaringHigh RiskElectronic Health RecordCessation Of LifeEventComparativeAdverse EventDiabetes MellitusAdverse Event RiskEffectivenessFollow-UpAlgorithms
Grant awards (7)
Long-term Cardiometabolic Disease in COVID-19$0
I01 · FY2025 · VA · contact PI
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications$0
I01 · FY2025 · VA · contact PI
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications$0
I01 · FY2024 · VA · contact PI
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications$0
I01 · FY2023 · VA · contact PI
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications$0
I01 · FY2023 · VA · contact PI
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications$0
I01 · FY2021 · VA · contact PI
Cause-specific Mortality among Users of Proton Pump Inhibitor$0
I21 · FY2020 · VA · contact PI